ABCLHealthcare · BiotechnologyThe 12 Wall Street analysts covering AbCellera Biologics, Inc. hold a median 12-month price target of $15 — +26.9% from the last close. Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 71 of 100 as at 24 Oct 2026 — in the upper half. Here, the model and the Street point the same way.
Consensus tells you what everyone already believes. The model scores AbCellera Biologics, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.
Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested
Momentum (97): The shares have been drifting up relative to others.
Volatility (24): The share price moves around a lot.
Built and run by Aslam Ghouse, an ex-Goldman Sachs quant trader with fourteen years in markets.
The bullish and bearish analyst opinions on ABCL, reported as data — targets and ratings, the market's view beside the model's.
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
Data provided by Twelve Data
The green dot is the last close — the median target sits +26.9% from it.
Of the 20 most recent actions, 3 moved their price target up and 0 moved it down.
| Date | Firm | Action | Rating | Target |
|---|---|---|---|---|
| 12 Oct 2026 | UBS | Initiates | Buy | $18 |
| 29 Sept 2026 | JP Morgan | Initiates | Overweight | $17 |
| 29 Sept 2026 | JP Morgan | Initiates | Overweight | — |
| 24 Sept 2026 | Goldman Sachs | Reinstates | Neutral | $13 |
| 11 Aug 2026 | Truist Securities | Maintains | Buy | — |
| 11 Aug 2026 | Truist Securities | Maintains | Buy | $12 → $30 |
| 6 Aug 2026 | Cantor Fitzgerald | Maintains | Overweight | $11 → $12 |
| 6 Aug 2026 | Cantor Fitzgerald | Maintains | Overweight | — |
| 6 Aug 2026 | Stifel | Maintains | Buy | $8.00 → $9.00 |
| 6 Aug 2026 | Stifel | Maintains | Buy | — |
| 7 July 2026 | Benchmark | Upgrade | Buy | $11 |
| 7 July 2026 | Benchmark | Upgrade | Buy | — |
| 5 May 2026 | Cantor Fitzgerald | Initiates | Overweight | — |
| 10 Apr 2026 | Jones Trading | Initiates | Buy | — |
| 7 Nov 2025 | Leerink Partners | Downgrade | Market Perform | — |
| 8 Aug 2025 | Stifel | Maintains | Buy | — |
| 14 July 2025 | Keybanc | Maintains | Overweight | — |
| 7 July 2025 | Leerink Partners | Assumes | Outperform | $5.00 |
| 16 May 2025 | Truist Securities | Maintains | Buy | — |
| 9 May 2025 | Stifel | Maintains | Buy | — |
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
ABCL appears in the Radar on the weeks it earns a place.
Both lines are total return — dividends reinvested — so the comparison is honest on both sides.
Over the twelve months to 23 Oct 2026, AbCellera Biologics, Inc. returned +107.0% against +14.3% for the S&P 500, dividends included.
Download this chart as an image — free to reuse; link this page as the source.
Data provided by Twelve Data
Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.
A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.
Cheaper than 97% of US stocks
Cheaper than 5% of US stocks
Cheaper than 23% of US stocks
Cheaper than 89% of US stocks
Higher than 3% of US stocks
Higher than 5% of US stocks
Higher than 5% of US stocks
Higher than 2% of US stocks
Higher than 32% of US stocks
Higher than 26% of US stocks
Higher than 1% of US dividend payers
Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.
The headline figures, each with its date. Every row carries its own link — cite it straight from here.
AbCellera Biologics, Inc. has a market value of $3.8B and an enterprise value of $3.2B.
Revenue in the twelve months to 30 June 2026: $66.2M. The latest quarter shrank 76.3% year on year.
Net income over the same four quarters: −$164.7M, a −248.8% net margin.
Free cash flow in the twelve months to 30 June 2026: −$119.7M.
Trailing P/E: −24.1×; forward P/E: −15.5× — the forward figure prices analyst consensus estimates, not reported earnings.
Forward dividend yield: 0.00%, paying out 0% of earnings.
AbCellera Biologics, Inc. employs 562 people — $118K of revenue per employee.
Data provided by Twelve Data
The nearest names by industry and size, scored by the same model — like for like.
Look up any of the roughly 4,600 stocks we score.
The rank is the raw material. Whether the rules would actually own AbCellera Biologics, Inc. — and when they’d sell — is the membership. See the Ticker Nerd 20 →
AbCellera announced that it will present at investor conferences in November 2026.
Why it matters — ABCL watchers may note the planned investor-conference appearances as an opportunity for the company to share updates with investors.
AbCellera announced that it will present Phase 1/2 data for ABCL635 at the TMS 2026 Annual Meeting.
Why it matters — ABCL watchers may be interested in the presentation as an update on clinical data for ABCL635.
AbCellera Biologics announced it will report its third quarter 2026 financial results on November 9, 2026. The announcement was made via Business Wire from the company's Vancouver, British Columbia headquarters.
Why it matters — ABCL watchers will care because the scheduled Q3 2026 earnings release provides a set date for investors to review the company's recent financial performance.
AbCellera's stock has surged 121% over three months, driven by positive data on its ABCL635 program, major partnerships, and a stronger financial position that have boosted investor confidence.
Why it matters — A watcher would care because the sharp rise reflects positive clinical data, new partnerships, and improved finances that are strengthening AbCellera's outlook.
AbCellera announced it will present Phase 2 data for ABCL635 at the IMS World Congress on Menopause 2026. The announcement was made via a press release from Vancouver, British Columbia.
Why it matters — The presentation of Phase 2 data for ABCL635 gives AbCellera watchers a view of clinical progress for one of the company's development candidates.
The 12 Wall Street analysts covering AbCellera Biologics, Inc. have a median 12-month price target of $15, with estimates ranging from $9 to $30. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.
Of the 12 analysts covering AbCellera Biologics, Inc., 11 rate it a Buy, 1 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks AbCellera Biologics, Inc. 71 out of 100 across roughly 4,600 US stocks as at 24 Oct 2026. None of this is personal advice — it does not consider your circumstances.
As at 24 Oct 2026, AbCellera Biologics, Inc. ranks 71 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Momentum (97 of 100).
No one can know that. What the data says: the median 12-month target from 12 analysts implies +26.9% from the last close, and Ticker Nerd's factor model ranks AbCellera Biologics, Inc. 71 out of 100 as at 24 Oct 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.
No analyst covering AbCellera Biologics, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for ABCL are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $9 to $30 over the next 12 months.
AbCellera Biologics, Inc. returned +107.0% over the 12 months to 23 Oct 2026, with dividends reinvested. Past performance does not indicate future returns.
AbCellera Biologics Inc. is a clinical-stage biotechnology company focused on discovering and developing antibody-based medicines.
The most recent item we track (Business Wire, 22 Oct 2026): "AbCellera to Present at Upcoming Investor Conferences in November 2026". AbCellera announced that it will present at investor conferences in November 2026.
AbCellera Biologics Inc. is a clinical-stage biotechnology company focused on discovering and developing antibody-based medicines. Its platform combines biology, computation, engineering, and data science to identify rare and potent antibodies from natural immune responses and advance them into drug programs. The company’s current work spans endocrinology and women’s health, immunology, oncology, and inflammation-related diseases, reflecting a broad therapeutic focus. AbCellera Biologics Inc. also develops an internal pipeline of antibody candidates and collaborates with biopharmaceutical partners on discovery and development programs. Its capabilities extend from target identification and antibody discovery through clinical manufacturing support, making it an integrated player in the antibody therapeutics market.
CEO Dr. Carl L.G. Hansen Ph.D. · 562 employees · Canada · https://www.abcellera.com
